Scarica l'app Stockscreener
110.04
8.92%
-10.78
Dopo l'orario di chiusura:
112.09
2.05
+1.86%
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Potential Tariffs Pose Challenges for Jazz Pharmaceuticals (JAZZ) - GuruFocus
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating - MarketScreener
Post-traumatic Stress Disorder Treatment Market Generated - openPR.com
After a year of 4.3% returns, Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) share price drop last week may have less of an impact on institutional investors - Yahoo Finance
JAZZ or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teacher Retirement System of Texas Buys 2,346 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - Eagle-Tribune
Dravet Syndrome Market Expected to Experience Major Growth - openPR
Jazz Pharma Reveals Growth Strategy: Key Updates Coming at Major Healthcare Conference - Stock Titan
Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Axsome's ADHD drug meets main goal in late-stage study - Marketscreener.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Jazz strikes the chord with $935m Chimerix acquisition - Xconomy
Based On Its ROE, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A High Quality Stock? - simplywall.st
Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride - Yahoo Finance
Chimerix Reports Fourth Quarter and Year End 2024 Financial Results - GlobeNewswire Inc.
Akari Therapeutics Appoints Biotechnology Industry Leader, - GlobeNewswire
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer - Yahoo Finance
Interesting JAZZ Put And Call Options For October 17th - Nasdaq
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect? - Yahoo Finance
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex® (cannabidiol) at American Academy of Neurology Annual Meeting - PR Newswire
Jazz Inks Insurer Class Deal As Xyrem Antitrust Trial Nears - Law360
JAZZ or ILMN: Which Is the Better Value Stock Right Now? - Yahoo Finance
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition? - Yahoo Finance
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock - Yahoo Finance
Jazz Pharmaceuticals EVP sells shares worth $332,604 By Investing.com - Investing.com South Africa
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant - Yahoo Finance
Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day - Zacks Investment Research
Bull of the Day: Jazz Pharmaceuticals (JAZZ) - Yahoo Finance
Insider Sell: Bruce Cozadd Sells 6,500 Shares of Jazz Pharmaceuticals PLC (JAZZ) - GuruFocus.com
Bull Of The Day: Jazz Pharmaceuticals (JAZZ) - Barchart
H.C. Wainwright lifts Jazz stock target to $217, maintains Buy By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - Defense World
HC Wainwright Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price - Defense World
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga India
Victory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS Group - Defense World
Robert Iannone Sells 7,080 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock - Defense World
Morgan Stanley Reiterates “Overweight” Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
Truist Financial Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $230.00 - Defense World
UBS Upgrades Jazz Pharmaceuticals (JAZZ) - Nasdaq
Jazz Pharmaceuticals Plc to Host Earnings Call - ACCESS Newswire
Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) - Defense World
UBS Upgrades Jazz Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $179 From $145 - Marketscreener.com
UBS raises Jazz Pharmaceuticals stock rating to Buy, target to $179 By Investing.com - Investing.com UK
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals - Nasdaq
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More - Nasdaq
Jazz Pharmaceuticals at TD Cowen Conference: Strategic Growth in Focus By Investing.com - Investing.com UK
Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating - Marketscreener.com
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio - MSN
Jazz Offers To Buy Chimerix For $935M To Boost Oncology Portfolio - Barchart
Truist lifts Jazz Pharma stock target to $230 on promising pipeline - Investing.com UK
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):